Chk1 inhibitor Gö6976 enhances the sensitivity of nasopharyngeal carcinoma cells to radiotherapy and chemotherapy in vitro and in vivo

Cancer Letters

Volumn 297, Issue 2, 2010, Pages 190-197

  Feng, Zizhen ^a   Xu, Shuangbing ^a,b,c   Liu, Mengzhong ^a   Zeng, Yi Xin ^a,b   Kang, Tiebang ^a,b  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b Department of Experimental Research ^*  (China)

^c HUBEI UNIVERSITY OF MEDICINE   (China)

Author keywords

Chemotherapy; G 6976; Nasopharyngeal carcinoma (NPC); Radiotherapy; Sensitizer

Indexed keywords

12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; CISPLATIN; CARBAZOLE DERIVATIVE; CHECKPOINT KINASE 1; PROTEIN KINASE; PROTEIN KINASE INHIBITOR;

APOPTOSIS; ARTICLE; CANCER RADIOTHERAPY; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL VIABILITY; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG STRUCTURE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; IONIZING RADIATION; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; CELL CYCLE; DRUG EFFECTS; DRUG POTENTIATION; DRUG SCREENING; ENZYMOLOGY; INFRARED RADIATION; METABOLISM; MOUSE; NASOPHARYNGEAL NEOPLASMS; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CARBAZOLES; CELL CYCLE; CELL LINE, TUMOR; CISPLATIN; DRUG SYNERGISM; HUMANS; INFRARED RAYS; MICE; MICE, NUDE; NASOPHARYNGEAL NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 77956405785     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.05.011     Document Type: Article

References (38)

1. Wei W.I., Sham J.S. Nasopharyngeal carcinoma. Lancet 2005, 365:2041-2054.
2. McDermott A.L., Dutt S.N., Watkinson J.C. The aetiology of nasopharyngeal carcinoma. Clin. Otolaryngol. Allied Sci. 2001, 26:82-92.
3. Young L.S., Rickinson A.B. Epstein-Barr virus: 40 years on. Nat. Rev. Cancer 2004, 4:757-768.
4. Al-Sarraf M., LeBlanc M., Giri P.G., Fu K.K., Cooper J., Vuong T., Forastiere A.A., Adams G., Sakr W.A., Schuller D.E., Ensley J.F. Chemo radiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J. Clin. Oncol. 1998, 16:1310-1317.
5. Dickson R.I., Flores A.D. Nasopharyngeal carcinoma: an evaluation of 134 patients treated between 1971 and1980. Laryngoscope 1985, 95:276-283.
6. Fandi A., Yanes B., Taamma A., Azli N., Armand J.P., Dupuis O., Eschwege F., Schwaab G., Cvitkovic E. Undifferentiated carcinoma of the nasopharynx: epidemiological, clinical and therapeutic aspects. Bull. Cancer 1994, 81:571-586.
7. Portugal J., Bataller M., Mansilla S. Cell death pathways in response to antitumor therapy. Tumori 2009, 95:409-421.
8. Choudhury A., Cuddihy A., Bristow R.G. Radiation and new molecular agents part I: targeting ATM-ATR checkpoints, DNA repair, and the proteasome. Sem. Radiat. Oncol. 2006, 16:51-58.
9. Xu B., Kim S.T., Lim D.S., Kastan M.B. Two molecularly distinct G(2)/M checkpoints are induced by ionizing irradiation. Mol. Cell Biol. 2002, 22:1049-1059.
10. Kastan M.B., Bartek J. Cell-cycle checkpoints and cancer. Nature 2004, 432:316-323.
11. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat. Rev. Cancer 2003, 3:155-168.
12. Jia X.Z., Yang S.Y., Zhou J., Li S.Y., Ni J.H., An G.S., Jia H.T. Inhibition of CHK1 kinase by Go6976 converts 8-chloro-adenosine-induced G2/M arrest into S arrest in human myelocytic leukemia K562 cells. Biochem. Pharmacol. 2009, 77:770-780.
13. Taylor W.R., Stark G.R. Regulation of the G2/M transition by p53. Oncogene 2001, 20:1803-1815.
14. Bunch R.T., Eastman A. Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor. Clin. Cancer Res. 1996, 2:791-797.
15. Graves P.R., Yu L., Schwarz J.K., Gales J., Sausville E.A., O'Connor P.M., Piwnica-Worms H. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J. Biol. Chem. 2000, 275:5600-5605.
16. Kohn E.A., Yoo C.J., Eastman A. The protein kinase C inhibitor Go6976 is a potent inhibitor of DNA damage-induced S and G2 cell cycle checkpoints. Cancer Res. 2003, 63:31-35.
17. Levesque A.A., Kohn E.A., Bresnick E., Eastman A. Distinct roles for p53 transactivation and repression in preventing UCN-01-mediated abrogation of DNA damage-induced arrest at S and G2 cell cycle checkpoints. Oncogene 2005, 24:3786-3796.
18. Perez R.P., Lewis L.D., Beelen A.P., Olszanski A.J., Johnston N., Rhodes C.H., Beaulieu B., Ernstoff M.S., Eastman A. Modulation of cell cycle progression in human tumors: a pharmacokinetic and tumor molecular pharmacodynamic study of cisplatin plus the Chk1 inhibitor UCN-01 (NSC 638850). Clin. Cancer Res. 2006, 12:7079-7085.
19. Wang Q., Fan S., Eastman A., Worland P.J., Sausville E.A., O'Connor P.M. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J. Natl. Cancer Inst. 1996, 88:956-965.
20. Martiny-Baron G., Kazanietz M.G., Mischak H., Blumberg P.M., Kochs G., Hug H., Marme D., Schachtele C. Selective inhibition of protein kinase C isozymes by the indolocarbazole Go 6976. J. Biol. Chem. 1993, 268:9194-9197.
21. Thorp K.M., Verschueren H., De Baetselier P., Southern C., Matthews N. Protein kinase C isotype expression and regulation of lymphoid cell motility. Immunology 1996, 87:434-438.
22. Gschwendt M., Dieterich S., Rennecke J., Kittstein W., Mueller H.J., Johannes F.J. Inhibition of protein kinase C mu by various inhibitors. Differentiation from protein kinase c isoenzymes. FEBS Lett. 1996, 392:77-80.
23. Patzold S., Schneider J., Rudolph C., Marme D., Schachtele C. Novel indolocarbazole protein kinase C inhibitors prevent reactivation of HIV-1 in latently infected cells. Antiviral Res. 1993, 22:273-283.
24. Arii K., Suehiro T., Ikeda Y., Kumon Y., Inoue M., Inada S., Takata H., Ishibashi A., Hashimoto K., Terada Y. Role of protein kinase C in pitavastatin-induced human paraoxonase I expression in Huh7 cells. Metabolism 2006.
25. Devadas K., Hewlett I.K., Dhawan S. Lipopolysaccharide suppresses HIV-1 replication in human monocytes by protein kinase C-dependent heme oxygenase-1 induction. J. Leukoc. Biol. 2006.
26. Oh Y.J., Youn J.H., Ji Y., Lee S.E., Lim K.J., Choi J.E., Shin J.S. HMGB1 is phosphorylated by classical protein kinase C and is secreted by a calcium-dependent mechanism. J. Immunol. 2009, 182:5800-5809.
27. Leung-Pineda V., Ryan C.E., Piwnica-Worms H. Phosphorylation of Chk1 by ATR is antagonized by a Chk1-regulated protein phosphatase 2A circuit. Mol. Cell Biol. 2006, 26:7529-7538.
28. Chen C.C., Kennedy R.D., Sidi S., Look A.T., D'Andrea A. CHK1 inhibition as a strategy for targeting Fanconi Anemia (FA) DNA repair pathway deficient tumors. Mol. Cancer 2009, 8:24.
29. Ishimi Y., Komamura-Kohno Y., Kwon H.J., Yamada K., Nakanishi M. Identification of MCM4 as a target of the DNA replication block checkpoint system. J. Biol. Chem. 2003, 278:24644-24650.
30. Crook T., Nicholls J.M., Brooks L., O'Nions J., Allday M.J. High level expression of deltaN-p63: a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC)?. Oncogene 2000, 19:3439-3444.
31. Saridakis V., Sheng Y., Sarkari F., Holowaty M.N., Shire K., Nguyen T., Zhang R.G., Liao J., Lee W., Edwards A.M., Arrowsmith C.H., Frappier L. Structure of the p53 binding domain of HAUSP/USP7 bound to Epstein-Barr nuclear antigen 1 implications for EBV-mediated immortalization. Mol. Cell 2005, 18:25-36.
32. Yip K.W., Shi W., Pintilie M., Martin J.D., Mocanu J.D., Wong D., MacMillan C., Gullane P., O'Sullivan B., Bastianutto C., Liu F.F. Prognostic significance of the Epstein-Barr virus, p53, Bcl-2, and survivin in nasopharyngeal cancer. Clin. Cancer Res. 2006, 12:5726-5732.
33. Hu Z.Y., Zhu X.F., Zhong Z.D., Sun J., Wang J., Yang D., Zeng Y.X. ApoG2, a novel inhibitor of antiapoptotic Bcl-2 family proteins, induces apoptosis and suppresses tumor growth in nasopharyngeal carcinoma xenografts. Int. J. Cancer 2008, 123:2418-2429.
34. Liang Y., Zhong Z., Huang Y., Deng W., Cao J., Tsao G., Liu Q., Pei D., Kang T., Zeng Y.X. Stem-like cancer cells are inducible by increasing genomic instability in cancer cells. J. Biol. Chem. 2010, 285:4931-4940.
35. Deng R., Tang J., Xia L.P., Li D.D., Zhou W.J., Wang L.L., Feng G.K., Zeng Y.X., Gao Y.H., Zhu X.F. Excisanin A, a diterpenoid compound purified from Isodon Macrocalyxin D, induces tumor cells apoptosis and suppresses tumor growth through inhibition of PKB/AKT kinase activity and blockade of its signal pathway. Mol. Cancer Ther. 2009, 8:873-882.
36. Kang T., Wei Y., Honaker Y., Yamaguchi H., Appella E., Hung M.C., Piwnica-Worms H. GSK-3 beta targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3 beta inactivation correlates with Cdc25A overproduction in human cancers. Cancer Cell 2008, 13:36-47.
37. Syljuasen R.G., Sorensen C.S., Nylandsted J., Lukas C., Lukas J., Bartek J. Inhibition of Chk1 by CEP-3891 accelerates mitotic nuclear fragmentation in response to ionizing radiation. Cancer Res. 2004, 64:9035-9040.
38. Chen Z., Xiao Z., Gu W.Z., Xue J., Bui M.H., Kovar P., Li G., Wang G., Tao Z.F., Tong Y., Lin N.H., Sham H.L., Wang J.Y., Sowin T.J., Rosenberg S.H., Zhang H. Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics. Int. J. Cancer 2006, 119:2784-2794.